BrainStorm Cell Therapeutics Inc. (BCLI) recently reported positive data, evaluating Cell therapy NurOwn or MSC-NTF cells as a treatment for progressive multiple sclerosis. The company stated that its phase two study observed improvements in secondary endpoints including diminishing inflammatory mechanisms, promoting repair and neurological functions.
A total of 20 patients were enrolled, out of which 18 were treated and 16 (80%) completed the clinical trials. However, two patients were excluded due to procedure-related adverse events. At no point did multiple sclerosis worsen and no co-relation of patient death with the treatment was concluded. Such positive data peaked investor interest with BCLI stock surging an approximate 21%.
However existing safety data of the recent study of NurOwn does not provide adequate effectiveness results to support the therapy’s approval, the U.S. Food and Drug Administration (FDA) stated in an initial statement.
About BrainStorm Cell Therapeutics Inc, NurOwn, And Progressive MS
BrainStorm Cell Therapeutics, Inc. (NASDAQ: BCLI) is a manufacturer for adult stem cell therapeutics for neurodegenerative diseases such as MS and holds the rights for producing and commercialization of NurOwn® technology holding a worldwide licensing agreement.
NurOwn technology targets disease pathways for neurodegenerative disorders by producing MSC-NTF cells from bone marrow that have been differentiated into a different cell, inevitably slowing down disease progression.
47% of patients on NurOwn treatment showed a minimum of 8-letter improvement in 7 months and 67% showed improvement in cognitive processing.
With a cash worth of US$42M and market capitalization of $252M, BCLI has had a stagnant increase in revenue and has the capability to increase company valuation via share dilution. However high-speed cash burns may indicate a weak balance sheet and volatile share prices may depict unstable growth for the company.
Conclusion
BrainStorm Cell Therapeutics Inc. (BCLI) has invested in a very lucrative market of Cell therapy NurOwn especially during the time of a pandemic. BCLI has pioneered gene cell therapy for neurodegenerative diseases such as MS and approval by FDA may prove to be extremely significant in increasing the company’s valuation.
